National Pension Service Has $27.07 Million Stake in Regeneron Pharmaceuticals Inc (REGN)

National Pension Service boosted its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 4.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 72,009 shares of the biopharmaceutical company’s stock after buying an additional 2,763 shares during the period. National Pension Service owned approximately 0.07% of Regeneron Pharmaceuticals worth $27,073,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in REGN. PNC Financial Services Group Inc. boosted its stake in Regeneron Pharmaceuticals by 5.0% during the second quarter. PNC Financial Services Group Inc. now owns 23,678 shares of the biopharmaceutical company’s stock valued at $11,630,000 after buying an additional 1,136 shares during the last quarter. Thrivent Financial For Lutherans lifted its stake in shares of Regeneron Pharmaceuticals by 2.2% in the 2nd quarter. Thrivent Financial For Lutherans now owns 2,850 shares of the biopharmaceutical company’s stock valued at $1,400,000 after purchasing an additional 60 shares during the last quarter. Mutual of America Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 1.7% in the 2nd quarter. Mutual of America Capital Management LLC now owns 9,267 shares of the biopharmaceutical company’s stock valued at $4,551,000 after purchasing an additional 153 shares during the last quarter. Rafferty Asset Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 2.9% in the 2nd quarter. Rafferty Asset Management LLC now owns 3,111 shares of the biopharmaceutical company’s stock valued at $1,528,000 after purchasing an additional 87 shares during the last quarter. Finally, MML Investors Services LLC lifted its stake in shares of Regeneron Pharmaceuticals by 42.1% in the 2nd quarter. MML Investors Services LLC now owns 3,834 shares of the biopharmaceutical company’s stock valued at $1,883,000 after purchasing an additional 1,136 shares during the last quarter. 65.69% of the stock is owned by institutional investors.

Several research firms have recently issued reports on REGN. Barclays lowered Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and lowered their price objective for the company from $450.00 to $395.00 in a research note on Friday, October 20th. Canaccord Genuity reaffirmed a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, October 16th. Jefferies Group reaffirmed a “hold” rating and issued a $421.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, February 2nd. Morgan Stanley raised their price objective on Regeneron Pharmaceuticals from $401.00 to $415.00 and gave the company an “equal weight” rating in a research note on Friday. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, November 28th. Four equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have issued a buy rating to the company. Regeneron Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $463.19.

Regeneron Pharmaceuticals Inc (REGN) traded up $13.76 on Friday, reaching $336.38. The firm has a market cap of $36,140.00, a PE ratio of 32.59, a P/E/G ratio of 1.27 and a beta of 1.47. Regeneron Pharmaceuticals Inc has a 1-year low of $314.99 and a 1-year high of $543.55. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 2.14.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping the consensus estimate of $4.18 by $1.05. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. Regeneron Pharmaceuticals’s quarterly revenue was up 28.9% on a year-over-year basis. During the same period last year, the business posted $3.04 EPS. research analysts anticipate that Regeneron Pharmaceuticals Inc will post 14.13 EPS for the current year.

WARNING: This story was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another domain, it was stolen and reposted in violation of United States and international trademark and copyright laws. The original version of this story can be accessed at https://stocknewstimes.com/2018/02/11/national-pension-service-grows-position-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply